Relaying what matters next.
The Relay is a new media project dedicated to covering slightly futuristic domains such as artificial intelligence, space exploration, longevity science, crypto and blockchain, advanced biology, and defense technologies. Our mission is to capture the signals of tomorrow and relay them forward with clarity, depth, and context.
What's happening today?
States vs. PJM: Data Centers Ignite a Governance Clash
AI demand and spiking capacity prices have jolted the Mid-Atlantic. Governors are challenging PJM’s authority, pressing for control over who pays, who builds, and which market rules will reshape the grid. Here is the playbook for the next two years.
Voice‑native agents arrive with Gemini Live audio
End-to-end voice models are leaving ASR-to-LLM-to-TTS pipelines behind. See how Gemini Live’s native audio changes latency, barge-in, emotion, and proactivity, what it enables across devices, where it still falls short, and how to build a production-ready agent now.
Nine EU banks bet on a euro stablecoin. What changes now?
Nine European banks have formed a Netherlands-based issuer to launch a MiCA‑compliant, euro‑pegged stablecoin as early as H2 2026. Here is how a bank‑issued token could reshape euro payments, on‑chain liquidity and cross‑border settlement, and what to watch before launch.
Earth's new quasi-moon could reboot small-body missions
Meet 2025 PN7, a newly identified Earth co-orbital whose Earth-like path turns deep space into a short hop. With low relative speeds and short transfer times, it invites rapid rendezvous, affordable sampling and even year-scale returns as Rubin and NEO Surveyor expand the pipeline.
Senolytics at St. Jude: frailty trial and aging vaccines
In August 2025, St. Jude’s SEN-SURVIVORS trial moved to active not recruiting, testing dasatinib plus quercetin against fisetin to boost walking speed and lower T‑cell p16INK4a in adult childhood‑cancer survivors. If the biomarker and function both shift, it could lay the groundwork for precision aging vaccines.
Drone-boat Alley: Gulf Coast shifts to 150-foot USV production
From Louisiana to Texas, commercial yards are shifting from prototypes to production on 150-foot unmanned surface vessels. Blue Water Autonomy’s pick of Conrad Shipyard and Saronic’s absorption of Gulf Craft point to a fast-forming cluster just as the Navy delays LUSV buys to Fiscal Year 2027.
EPA’s 2025 Data Blackout: How Power Markets Will React
EPA has moved to end federal greenhouse gas reporting and repeal power-plant CO2 standards, creating a national emissions data gap. Here is how state programs, utility planning, capacity markets, corporate procurement, and project finance will adapt next.
Onshore Crypto Perps Arrive: Cboe and Coinbase Redraw Market
September 2025 ushers perpetual-style crypto leverage onto U.S. venues. Cboe’s Continuous futures and Coinbase’s CFTC-regulated perps promise deeper liquidity, new basis triangles, and funding capture on home turf while testing fresh guardrails for institutions and retail.
SEC fast-tracks spot crypto ETFs with new generic rules
On September 17 and 18, 2025, the SEC approved generic listing standards that let NYSE Arca, Nasdaq, and Cboe list qualifying spot commodity ETPs, including crypto, without individualized 19b-4 orders. Here is what changed, why it matters, and what could list next.
The West’s day-ahead showdown: EDAM vs. Markets+ by 2027
The West is splitting into two day-ahead hubs as CAISO’s EDAM starts in 2026 and SPP’s Markets+ aims for 2027. See who is joining which market, the go-live timeline, and what the split means for prices, reliability, congestion rents, and investment signals.
Inside Boeing’s F‑47 NGAD and the Manned Unmanned Air Stack
Boeing’s F‑47 win on March 21, 2025 reset the air superiority race. This deep dive shows how an open architecture fighter, teamed with Collaborative Combat Aircraft and adaptive propulsion, could redefine U.S. power and the defense industrial base through the 2030s.
NASA’s 2025 Mars sample return reset, explained
NASA rebooted Mars Sample Return in 2025 with a two-architecture race and new fixed-price roles for industry. Here is what changed, why it matters for cost, schedule, and risk, and what the science payoff could be.
Lp(a) goes mainstream: RNA shots reset lifelong heart risk
In March 2025, lepodisiran delivered striking and durable Lp(a) reductions, while pelacarsen’s first outcomes readout is guided for 2026. Here is why Lp(a) is causal, why lifestyle will not fix it, and how rare dosing could reshape midlife heart risk.
Claude joins 365 Copilot: the multi model enterprise playbook
Microsoft just added Anthropic’s Claude Sonnet 4 and Opus 4.1 to Microsoft 365 Copilot and Copilot Studio on September 24 to 25, 2025. Here is a pragmatic playbook for CIOs to route across models, raise reliability, control costs, and govern a new cross cloud trust boundary.
DBS brings sgBENJI and RLUSD to XRPL for 24/7 money markets
DBS is listing Franklin Templeton’s sgBENJI tokenized money market fund alongside Ripple’s RLUSD on the DBS Digital Exchange, creating a bank-grade loop between stablecoin liquidity and yield with repo next. Here is why this 24/7 rail on XRPL could be the template for on-chain money markets.
AWS lines up Quick Suite to own the enterprise agent stack
AWS is reshuffling leadership ahead of a late September 2025 debut for Quick Suite, a user-facing layer on Amazon Q that unifies runtime, tooling, connectors, and Marketplace into an enterprise AgentOps platform. Here is what is shipping, how it fits together, and a two‑quarter plan to deploy production agents with cost and security controls.
Baltic GPS War: How Jamming Forces a NATO PNT Rethink
A September surge in GPS jamming and spoofing across the Baltic and NATO’s Eastern Sentry response are forcing a fast reset in how allied forces navigate, time, and fight in contested skies and seas.
Alzheimer’s enters the bloodstream: pTau217 tests arrive
From the May 16, 2025 FDA clearance to an August nationwide rollout, a plasma pTau217 blood test is reshaping how we detect Alzheimer’s pathology. See who should be tested, how to interpret results, and what this means for care, prevention, and access.
















